AbbVie won an FDA approval for Decnupaz (pivekimab sunirine) to treat adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The antibody-drug conjugate is CD123-targeted and received clearance based on data from the global Cadenza Phase 1/2 study. The approval adds to AbbVie’s hematology pipeline momentum following its 2023 ImmunoGen acquisition, which brought the asset into AbbVie’s fold. BPDCN remains an ultra-rare, aggressive blood cancer with limited treatment options, and ADC approvals in this niche can accelerate both clinical adoption and future competitive positioning for CD123-directed programs. The decision also underscores how acquisition-driven ADC portfolios are translating into regulatory outcomes—potentially tightening timeline pressure for rivals with late-stage CD123 or similar myeloid-targeted conjugates.